Intellia Therapeutics (NTLA) Announces Fiscal Q4 and Full Year 2025 Financial Results

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the top gene therapy stocks to buy according to hedge funds. Intellia Therapeutics, Inc. (NASDAQ:NTLA) announced its fiscal Q4 and full year 2025 financial results on February 26, reporting cash, cash equivalents, and marketable securities of $605.1 million as of December 31, 2025, compared to $861.7 million in the prior year period. The company expects its cash, cash equivalents, and marketable securities as of December 31, 2025, to fund operations into ...